Transaction · 0001193125-26-382456
CORTCORCEPT THERAPEUTICS INC
Vieira Roberto Wandenkolk
Vieira Roberto Wandenkolk, PRES, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 23600.000000 shares for an estimated $2580674.16. Reported holdings after the transaction were 38975.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Open-market sellSEC transaction code SPRES
- Trade date
- Sep 02, 2026
- Filing date
- Sep 04, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 62,575 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CORT price since this filing
Daily closing prices, with the filing date and available return windowsCORT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1.1%1w ago +7.3%1d ago +1.6%
Returns since7d +1.0%30d +4.1%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-382456 Common Stock
- Transaction date
- Sep 02, 2026 Filed Sep 04, 2026, 01:02 AM · 2d delay
- Shares
- 23,600 sh $109.35 per share
- Estimated value
- -$2.58M Computed from shares × price
- Holdings after
- 38,975 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Holdings Reduction Large Sale 10b5-1 Detected
Filing-only score
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
President, Oncology
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…
- F2
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- F3
Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to th…
- F4
Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…
- F5
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- F6
The closing price on September 1, 2026 was used to calculate the withholding obligation.
- F7
Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the…
- F8
This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the…
- F9
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each…
- F10
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each…
- F11
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each…
- F12
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each…
- F13
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each…
- F14
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each…
- F15
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each…
- F16
Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable…
Related transactions
Same SEC filing0 other transactions
Recent company activity
CORT0 recent txs